



Izervay™ (avacincaptad pegol) (Intravitreal)

Document Number: IC-0721

Last Review Date: 09/05/2023

Date of Origin: 09/05/2023

Dates Reviewed: 09/2023

I. Length of Authorization

Coverage will be provided every six months and may be renewed for up to 12 months (i.e., 12 doses per each eye) of total therapy.

II. Dosing Limits

A. Quantity Limit (max daily dose) [NDC unit]:

- Izervay 2 mg/0.1 mL solution for injection in a single-dose vial: 1 vial per eye every 28 days

B. Max Units (per dose and over time) [HCPCS Unit]:

- 4 mg every 28 days up to 12 months
(Max units are based on administration to BOTH eyes)

III. Initial Approval Criteria ^{1,2}

Coverage is provided in the following conditions:

- Patient is at least 18 years of age; **AND**
- Patient has a baseline assessment for all the following: best corrected visual acuity (BCVA), fundus autofluorescence (FAF) imaging, and optical coherence tomography (OCT); **AND**

Universal Criteria

- Patient is free of ocular and/or peri-ocular infections; **AND**
- Patient does not have active intraocular inflammation; **AND**
- Will not be used in combination with other intravitreal complement inhibitor therapies; **AND**
- Patient does not have category 6, or higher, visual impairment or blindness (i.e., no light perception-total blindness); **AND**

Geographic Atrophy (GA) † 1,2,3

- The patient has a diagnosis of GA as defined by a phenotype of central geographic atrophy having 1 or more zones of well demarcated retinal pigmented epithelium (RPE) and/or choriocapillaris atrophy; **AND**
- Disease is secondary to age-related macular degeneration (AMD); **AND**
- Conditions other than AMD have been ruled out (e.g., Stargardt disease, cone rod dystrophy, toxic maculopathies, etc.)

† FDA Approved Indication(s); ‡ Compendium recommended indication(s); Ⓢ Orphan Drug

IV. Renewal Criteria ^{1,2}

Coverage can be renewed based upon the following criteria:

- Patient continues to meet the universal and indication-specific relevant criteria as identified in section III; **AND**
- Absence of unacceptable toxicity from the drug. Examples of unacceptable toxicity include: endophthalmitis, retinal detachment, neovascular (wet) AMD or choroidal neovascularization, increased intraocular pressure, etc. that cannot be adequately treated; **AND**
- Patient has had disease stabilization or slowing of the rate of disease progression while on therapy compared to pre-treatment baseline as measured by any of the following:
 - Best corrected visual acuity (BCVA)
 - Fundus Autofluorescence (FAF)
 - Optical Coherence Tomography (OCT); **AND**
- Continued administration is necessary for the maintenance treatment of the condition and the patient and provider have discussed potential decrease in frequency administrations; **AND**
- Patient has not received a total of 12 months (i.e., 12 doses per each eye) of therapy

V. Dosage/Administration ¹

| Indication | Dose |
|--|--|
| Geographic Atrophy | The recommended dose for Izervay is 2 mg (0.1 mL of 20 mg/mL solution) administered by intravitreal injection to each affected eye once monthly (approximately every 28 ± 7 days) for up to 12 months. |
| <ul style="list-style-type: none">- Keep refrigerated. Prior to use, allow Izervay to reach room temperature, and may be kept at room temperature for up to 24 hours.- Each vial and syringe should only be used for the treatment of a single eye. | |

VI. Billing Code/Availability Information

HCPCS Code:

- J3490 – Unclassified drugs

- C9399 – Unclassified drugs or biologicals (*hospital outpatient use*)

NDC:

- Izervay 2 mg/0.1 mL solution for injection in a single-dose vial: 82829-0002-xx

VII. References

1. Izervay [package insert]. Parsippany, NJ; Iveric bio, Inc.; August 2023. Accessed August 2023.
2. Jaffe GJ, Westby K, Csaky KG, et al. C5 Inhibitor avacincaptad pegol for geographic atrophy due to age-related macular degeneration: a randomized pivotal phase 2/3 trial. *Ophthalmology*. 2021; 128: 576-586.
3. American Academy of Ophthalmology-Preferred Practice Patterns (AAO-PPP) Retina/Vitreous Committee, Hoskins Center for Quality Eye Care. Age-Related Macular Degeneration PPP – Update 2019. Oct 2019.

Appendix 1 – Covered Diagnosis Codes

| ICD-10 | ICD-10 Description |
|----------|--|
| H35.3113 | Nonexudative age-related macular degeneration, right eye advanced atrophic without subfoveal involvement |
| H35.3114 | Nonexudative age-related macular degeneration, right eye advanced atrophic with subfoveal involvement |
| H35.3123 | Nonexudative age-related macular degeneration, left eye advanced atrophic without subfoveal involvement |
| H35.3124 | Nonexudative age-related macular degeneration, left eye advanced atrophic with subfoveal involvement |
| H35.3133 | Nonexudative age-related macular degeneration, bilateral eye advanced atrophic without subfoveal involvement |
| H35.3134 | Nonexudative age-related macular degeneration, bilateral eye advanced atrophic with subfoveal involvement |
| H35.3193 | Nonexudative age-related macular degeneration, unspecified eye advanced atrophic without subfoveal involvement |
| H35.3194 | Nonexudative age-related macular degeneration, unspecified eye advanced atrophic with subfoveal involvement |

Appendix 2 – Centers for Medicare and Medicaid Services (CMS)

Medicare coverage for outpatient (Part B) drugs is outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals. In addition, National Coverage Determination (NCD), Local Coverage Determinations (LCDs), and Local Coverage Articles (LCAs) may exist and compliance with these policies is required where applicable. They can be found at: <https://www.cms.gov/medicare-coverage-database/search.aspx>. Additional indications may be covered at the discretion of the health plan.

Medicare Part B Covered Diagnosis Codes (applicable to existing NCD/LCD/LCA):

| Medicare Part B Administrative Contractor (MAC) Jurisdictions | | |
|---|---|---|
| Jurisdiction | Applicable State/US Territory | Contractor |
| E (1) | CA, HI, NV, AS, GU, CNMI | Noridian Healthcare Solutions, LLC |
| F (2 & 3) | AK, WA, OR, ID, ND, SD, MT, WY, UT, AZ | Noridian Healthcare Solutions, LLC |
| 5 | KS, NE, IA, MO | Wisconsin Physicians Service Insurance Corp (WPS) |
| 6 | MN, WI, IL | National Government Services, Inc. (NGS) |
| H (4 & 7) | LA, AR, MS, TX, OK, CO, NM | Novitas Solutions, Inc. |
| 8 | MI, IN | Wisconsin Physicians Service Insurance Corp (WPS) |
| N (9) | FL, PR, VI | First Coast Service Options, Inc. |
| J (10) | TN, GA, AL | Palmetto GBA, LLC |
| M (11) | NC, SC, WV, VA (excluding below) | Palmetto GBA, LLC |
| L (12) | DE, MD, PA, NJ, DC (includes Arlington & Fairfax counties and the city of Alexandria in VA) | Novitas Solutions, Inc. |
| K (13 & 14) | NY, CT, MA, RI, VT, ME, NH | National Government Services, Inc. (NGS) |
| 15 | KY, OH | CGS Administrators, LLC |